{"id":"https://openalex.org/W2595594792","doi":"https://doi.org/10.1182/blood.v118.21.4181.4181","title":"Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales,","display_name":"Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales,","publication_year":2011,"publication_date":"2011-11-18","ids":{"openalex":"https://openalex.org/W2595594792","doi":"https://doi.org/10.1182/blood.v118.21.4181.4181","mag":"2595594792"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v118.21.4181.4181","doi":"https://doi.org/10.1182/blood.v118.21.4181.4181","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v118.21.4181.4181","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110046791","display_name":"Stephen Schey","orcid":"https://orcid.org/0000-0002-2474-9484","observed_orcids":["https://orcid.org/0000-0002-2474-9484"]},"institutions":[{"id":"https://openalex.org/I4210153400","display_name":"King's College Hospital","ror":"https://ror.org/044nptt90","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210111135","https://openalex.org/I4210153400"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen Schey","raw_affiliation_strings":["Haematology, King's College Hospital, London, United Kingdom,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Haematology, King's College Hospital, London, United Kingdom,","institution_ids":["https://openalex.org/I4210153400"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064579837","display_name":"Sean Stern","orcid":"https://orcid.org/0009-0002-5266-8371","observed_orcids":["https://orcid.org/0009-0002-5266-8371"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Sean Stern","raw_affiliation_strings":["United BioSource Corporation, bethesda, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"United BioSource Corporation, bethesda, MD, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090001740","display_name":"Sujith Dhanasiri","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Sujith Dhanasiri","raw_affiliation_strings":["Celgene Ltd, Uxbridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Ltd, Uxbridge, United Kingdom","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"Ruth Brown","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Ruth Brown","raw_affiliation_strings":["United BioSource Corporation, bethesda, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"United BioSource Corporation, bethesda, MD, USA,","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5064579837","https://openalex.org/A5090001740"],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.1886,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.62983792,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"118","issue":"21","first_page":"4181","last_page":"4181"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.7675999999046326,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.7675999999046326,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.2232999950647354,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9760000109672546},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9660000205039978},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.8040000200271606},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8640000224113464},{"id":"https://openalex.org/keywords/economic-modeling","display_name":"economic modeling","score":0.5799999833106995},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.6830000281333923},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8090000152587891},{"id":"https://openalex.org/keywords/post-progression-survival","display_name":"post-progression survival","score":0.7919999957084656},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8050000071525574},{"id":"https://openalex.org/keywords/nice-guidance","display_name":"NICE guidelines","score":0.5889999866485596},{"id":"https://openalex.org/keywords/thalidomide","display_name":"thalidomide","score":0.8640000224113464},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/patient-access-schemes","display_name":"patient access schemes","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.8746541738510132},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7437204122543335},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.715764045715332},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6617072820663452},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6221455335617065},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5730520486831665},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.5331838130950928},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.5004186630249023},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.49834275245666504},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4928877353668213},{"id":"https://openalex.org/C2779256446","wikidata":"https://www.wikidata.org/wiki/Q33959","display_name":"Nice","level":2,"score":0.4921826422214508},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.48434555530548096},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.42779797315597534},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3631066083908081},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2752786874771118},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1182/blood.v118.21.4181.4181","doi":"https://doi.org/10.1182/blood.v118.21.4181.4181","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v118.21.4181.4181","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/f495dc80-f13c-49d6-b032-f47b577327fe","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/f495dc80-f13c-49d6-b032-f47b577327fe","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Schey, S, Stern, S, Dhanasiri, S & Brown, R 2011, 'Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales', Blood, vol. 118, no. 21, pp. 1789 - 1790.","raw_type":"article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3047575701","https://openalex.org/W2004864382","https://openalex.org/W1974135782","https://openalex.org/W2022036807","https://openalex.org/W3042537788","https://openalex.org/W2041042375","https://openalex.org/W2515657367","https://openalex.org/W2462844398","https://openalex.org/W1980068016","https://openalex.org/W2058009067"],"abstract_inverted_index":{"Abstract":[0,1],"4181":[2],"Introduction:":[3],"Lenalidomide":[4],"plus":[5],"dexamethasone":[6],"(Len+Dex)":[7],"is":[8,507,562,566,585],"approved":[9],"by":[10,328,526],"EMA":[11],"for":[12,38,60,111,129,175,179,198,234,256,379,421,487,509,528,555,568,587],"patients":[13,61,159,190,199,214,285,306,532,590],"with":[14,52,74,191,404,533,559],"multiple":[15],"myeloma":[16],"(MM)":[17],"who":[18,165],"have":[19],"received":[20,167,286],"at":[21,220,504],"least":[22],"1":[23,169,193],"prior":[24,170,194,307,537],"therapy.":[25,171,195,579],"In":[26],"the":[27,46,63,85,90,93,133,138,161,201,207,229,236,242,247,270,323,424,434,439,443,481,484,540,572,593],"wake":[28],"of":[29,41,87,92,140,158,189,213,266,289,294,322,406,412,453,459,576,600],"NICE's":[30],"guidance":[31],"on":[32,215,311,470],"Thalidomide":[33],"and":[34,76,99,118,144,185,258,278,303,317,355,373,382,410,455,473,547,574,591],"Bortezomib":[35],"TA":[36],"228":[37],"1st-line":[39],"treatment":[40,180,183,553],"MM,":[42],"Len+Dex":[43,88,182,219,226,392,422,503,522,584],"may":[44],"be":[45],"only":[47,168,192,477,523],"available":[48],"novel":[49,511,560],"therapy":[50,558],"option":[51],"potential":[53],"to":[54,83,109,218,305,308,401,466,518,544,570],"extend":[55],"survival":[56,120,147,430,489],"beyond":[57,291],"traditional":[58],"therapies":[59,538],"failing":[62],"NICE":[64,360,527,542],"recommended":[65,525],"initial":[66],"treatments;":[67],"thalidomide":[68,546],"or":[69,535],"bortezomib":[70],"both":[71],"in":[72,122,228,269,388,397,447,513,530,549],"combination":[73,139],"melphalan":[75],"prednisone.":[77],"Therefore,":[78],"economic":[79],"modelling":[80,368],"was":[81,107,135,152,203,223,239,261,483],"undertaken":[82],"evaluate":[84],"cost-effectiveness":[86],"from":[89,154,160,206,246,275,300],"perspective":[91],"National":[94],"Health":[95],"Service":[96],"(NHS),":[97],"England":[98],"Wales.":[100],"Methods:":[101],"An":[102],"Excel-based":[103],"individual":[104,131,332],"simulation":[105],"model":[106,134,202,324,333,462],"developed":[108],"account":[110,233],"disease":[112,516],"history":[113],"which":[114],"affects":[115],"time-to-progression":[116],"(TTP)":[117],"overall":[119],"(OS)":[121],"relapse":[123],"refractory":[124],"MM":[125,531],"patients.":[126],"The":[127,149,172,196,320,417,461,476],"OS":[128],"each":[130],"within":[132,200],"calculated":[136],"as":[137],"that":[141,479,502,583],"patient's":[142],"TTP":[143,150,176],"post":[145],"progression":[146,309],"(PPS).":[148],"efficacy":[151],"derived":[153,173,205],"a":[155,224,264,280,370,375,394,448,510],"subgroup":[156],"analysis":[157,468,581],"MM-009/010":[162,208],"pivotal":[163],"trials":[164],"had":[166,393],"equation":[174],"included":[177,279],"parameters":[178,334,472],"response,":[181],"effect":[184,227],"certain":[186],"baseline":[187],"characteristics":[188],"PPS":[197,238],"also":[204],"trials;":[209],"however,":[210,429],"since":[211],"47%":[212],"Dex":[216,230,237,402,488,519],"switched":[217],"progression,":[221],"there":[222],"significant":[225],"PPS.":[231],"To":[232],"this,":[235],"calibrated":[240],"using":[241],"longer":[243],"follow":[244],"up":[245],"UK":[248],"Medical":[249],"Research":[250],"Council":[251],"(MRC)":[252],"trials.":[253],"Resource":[254],"use":[255,529],"monitoring":[257],"adverse":[259],"events":[260],"obtained":[262],"via":[263],"survey":[265],"expert":[267],"hematologists":[268],"UK.":[271],"Costs":[272],"were":[273,298,326,335,365,427],"taken":[274,299],"NHS":[276],"sources":[277],"Patient":[281],"Access":[282],"Scheme":[283],"where":[284],"Len":[287],"free":[288],"charge":[290],"26":[292],"cycles":[293],"use.":[295],"Utility":[296],"values":[297],"published":[301],"literature":[302],"applied":[304],"(based":[310],"their":[312,338],"best":[313],"response":[314],"rate":[315,378],"achieved)":[316],"after":[318],"progression.":[319],"robustness":[321],"results":[325,463,482,500],"assessed":[327],"sensitivity":[329,467],"analyses":[330],"whereby":[331],"varied":[336,491],"across":[337,492],"confidence":[339],"intervals":[340],"(CI).":[341],"Results":[342],"reported":[343],"include":[344],"life-years":[345,348],"(LY),":[346],"quality-adjusted":[347],"(QALY),":[349],"costs,":[350],"cost":[351,356,440,449,596],"per":[352,357,450,456,597],"LY":[353,451],"gained":[354,452,458],"QALY":[358,457,598],"gained.":[359],"technology":[361],"appraisal":[362],"methodology":[363],"guidelines":[364],"followed":[366],"when":[367,490],"over":[369,423,433],"lifetime":[371,426],"horizon":[372],"applying":[374],"3.5%":[376],"discount":[377],"future":[380],"benefits":[381,431,575],"costs.":[383],"All":[384],"costs":[385,420,573],"presented":[386],"are":[387],"British":[389],"pounds.":[390],"Results:":[391,603],"substantial":[395],"increase":[396],"health-related":[398],"outcomes":[399],"compared":[400,517],"alone,":[403],"LYs":[405],"5.37":[407],"vs.":[408,414],"2.15":[409],"QALYs":[411],"3.69":[413],"1.49,":[415],"respectively.":[416],"associated":[418],"drug":[419,512],"patients'":[425],"higher:":[428],"accrued":[432],"same":[435],"time":[436],"period":[437],"offset":[438],"differences":[441],"between":[442],"two":[444],"regimens,":[445],"resulting":[446],"20,639":[454],"30,153.":[460],"remained":[464],"robust":[465],"conducted":[469],"most":[471],"utility":[474],"estimates.":[475],"parameter":[478],"affected":[480],"adjustment":[485],"factor":[486],"its":[493],"95%":[494],"CI":[495],"(see":[496],"table).":[497],"Discussion:":[498],"These":[499],"indicated":[501],"2nd":[505,556,577,588],"line":[506,557,578,589],"cost-effective":[508,586],"an":[514],"orphan":[515],"alone.":[520],"Despite":[521],"being":[524],"2":[534],"more":[536,563],"(with":[539],"recent":[541],"decision":[543],"allow":[545],"Velcade":[548],"de":[550],"novo":[551],"patients),":[552],"alternatives":[554],"agents":[561],"limited.":[564],"It":[565],"important":[567],"clinicians":[569],"consider":[571],"This":[580],"demonstrated":[582],"meets":[592],"commonly":[594],"quoted":[595],"threshold":[599],"30,000.":[601],"Modelled":[602],"Disclosures:":[604],"Schey:":[605],"Celgene:":[606,612,620],"Consultancy.":[607,613,621],"Stern:United":[608],"BioSource":[609,617],"Corporation:":[610,618],"Employment;":[611,619],"Dhanasiri:Celgene:":[614],"Employment.":[615],"Brown:United":[616]},"counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}